Release date: 2018-05-10
A new study from Japanese scientists found that the level of cytoskeleton-associated protein 4 (CKAP4) in the blood of patients with lung cancer was significantly higher than that of healthy individuals. The researchers also determined that CKAP4 levels have increased in the blood of patients with stage I disease, making it a potential non-invasive diagnostic marker for changing certain lung cancers (including non-small cell lung cancer and squamous cells). Cancer, etc.) current diagnosis and treatment methods, and improve the prognosis of patients.
Image source: cityofhope
The latest results were published in the American Journal of Pathology on May 8th, entitled "Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer", Dr. Ryo Nagashio, Kitasato University, Japan Dr. Yuichi Sato is the correspondent and lead author respectively.
Https://doi.org/10.1016/j.ajpath.2018.03.007
Dr. Ryo Nagashio said: "Current biomarkers for lung cancer include carcinoembryonic antigen (CEA), sialyl Lewis X antigen (SLX), squamous cell carcinoma (SCC) antigen and cytokeratin fragment (CYFRA) 21-1, but these Biomarkers are not sensitive enough to detect tumors early, and our research provides evidence that CKAP4 may be a new early serum diagnostic marker for lung cancer."
In order to develop this serum diagnostic marker for lung cancer, we further studied an antibody called KU-Lu-1 that recognizes CKAP4 and evaluated the value of the antibody as a serological diagnostic marker for lung cancer. The researchers studied 271 patients with lung cancer and The sera of 100 healthy individuals were subjected to reverse-phase protein array analysis.
The trial found that serum CKAP4 levels can distinguish between lung cancer patients and healthy controls. Serum CKAP4 levels in patients with stage I adenocarcinoma or squamous cell carcinoma were higher than in healthy controls (P < 0.0001), whereas elevated levels of CKAP4 were also detected in stage I non-small cell lung cancer. The following validation trials also confirmed that serum CKAP4 levels were significantly higher in lung cancer patients than in healthy controls (P < 0.0001), suggesting that CKAP4 may be a new early serological diagnostic marker for lung cancer.
Previous experiments have shown that in the disease stage I - IV, the sensitivities of serum CEA, CYFRA and SCCA are 30%-52%, 17%-82% and 24%-39%, respectively. In the latest study, the scientists found that the sensitivity of serum CKAP4 was 81% in the training set and 69% in the validation group, both higher than the sensitivity of current serum diagnostic markers.
Subsequently, by immunoprecipitation and mass spectrometry, the panel determined that the KU-Lu-1 antibody recognizes CKAP4 in lung cancer cells and tissues and confirmed its secretion into the culture supernatant. Further, the researchers validated the results using 100 lung cancer patients and 38 healthy controls.
"The use of CKAP4 as a biomarker can change the current practice of treating patients with lung cancer. In addition, the combination of CKAP4 and conventional markers can significantly improve the diagnostic accuracy," Dr. Sato concluded.
Reference materials:
Lung Cancer Biomarker Discovery Raises Hopes for Early Detection
Source: Bio-Exploration
Two-Piece Baseplate,2 Piece Colostomy Bags Chassis,Ostomy Bags Chassis,Hypoallergenic Ostomy Chassis
Wenzhou Celecare Medical Instruments Co.,Ltd , https://www.wzcelecare.com